Valuation: Edgewise Therapeutics, Inc.

Market Cap 4.27B 3.74B 3.45B 3.19B 6.01B 411B 6.12B 41.18B 16.16B 201B 16.06B 15.7B 692B P/E 2026 *
-20.7x
P/E 2027 * -24.5x
Enterprise Value 2.58B 2.25B 2.08B 1.92B 3.62B 248B 3.69B 24.83B 9.74B 121B 9.68B 9.47B 417B EV / Sales 2026 *
12.3x
EV / Sales 2027 * 55.4x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Edgewise Therapeutics, Inc.

1 day-3.73%
1 week-7.88%
Current month-2.22%
1 month+14.07%
3 months+19.81%
6 months+41.04%
Current year+60.10%
1 week 38.45
Extreme 38.45
48.4
1 month 30.84
Extreme 30.84
48.4
Current year 22.78
Extreme 22.78
48.4
1 year 12.3
Extreme 12.3
48.4
3 years 5.12
Extreme 5.12
48.4
5 years 5.12
Extreme 5.12
48.4
10 years 5.12
Extreme 5.12
48.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 56 2017-05-31
Chief Executive Officer 65 2017-07-31
Director of Finance/CFO 55 2025-11-09
Director TitleAgeSince
Director/Board Member 65 2017-05-31
Chairman 66 2017-07-31
Director/Board Member 56 2017-07-31
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Founder

600,000 0.5577%
06-30Free

Director

319 0.0003%
06-04Free

Director

16,377 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%-7.88%+185.21%+450.28% 4.27B
-0.66%-5.50%+57.13%+72.71% 54.49B
+6.05%+7.79%+62.23%+88.46% 55.93B
+0.89%-2.42%+8.07%+434.51% 23.87B
+0.37%-4.13%-18.56%-16.48% 22.86B
+3.51%+10.88%+44.84%-3.21% 20B
+0.59%-1.11%+37.47%-30.34% 17.48B
-4.00%-10.96%+181.91%+328.17% 15.39B
+7.69%+11.91%+50.03%+720.96% 15.19B
-0.48%-2.30%+22.36%+187.62% 14.02B
Average +1.02%-2.46%+63.07%+223.27% 24.35B
Weighted average by Cap. +1.82%-0.60%+51.66%+159.62%

Financials

2026 *2027 *
Net sales 209M 183M 169M 156M 294M 20.11B 300M 2.02B 791M 9.85B 786M 769M 33.91B 46.67M 40.78M 37.7M 34.83M 65.59M 4.48B 66.78M 450M 176M 2.19B 175M 171M 7.56B
Net income -207M -180M -167M -154M -290M -19.84B -296M -1.99B -781M -9.71B -776M -759M -33.45B -174M -152M -141M -130M -245M -16.73B -249M -1.68B -658M -8.19B -654M -640M -28.21B
Net Debt -1.7B -1.48B -1.37B -1.27B -2.39B -163B -2.43B -16.35B -6.42B -79.83B -6.38B -6.23B -275B -1.69B -1.48B -1.36B -1.26B -2.37B -162B -2.42B -16.27B -6.39B -79.46B -6.35B -6.21B -274B
Logo Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Employees
154
Date Price Change Volume
26-07-14 US$39.73 -3.73% 1,212,749
26-07-13 US$41.27 -9.12% 1,037,527
26-07-10 US$45.41 -6.08% 1,068,174
26-07-09 US$48.35 +4.43% 1,590,676
26-07-08 US$46.30 +7.35% 2,469,178
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
39.73USD
Average target price
49.15USD
Spread / Average Target
+23.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EWTX Stock